Eli Lilly (LLY) benefits from "lots of untapped volume to capture" in the obesity drug market ever after Zepbound's exclusion from CVS Health's (CVS) preferred list, Deutsche Bank said Friday in a note.
"Commercialization of the chronic obesity opportunity is still in early innings" after Lilly's Zepbound launched in December 2023 and Novo Nordisk's (NVO) Wegovy debuted in June 2021, the report said.
Customers are likely opting for Zepbound after trials demonstrating a 20% weight loss advantage versus Wegovy at 14% after 72 weeks, Deutsche Bank said.
Zepbound's cash-pay vial at $349 to $499 a month is "virtually on par with Wegovy's new to brand scripts," the report said.
Deutsche Bank reiterated its buy rating on Lilly stock with a 12-month target price of $1,010.
Lilly shares rose 2.9% in recent Friday trading, and Novo Nordisk jumped 5.3%.
Price: 816.97, Change: +22.87, Percent Change: +2.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。